The Royal Netherlands Academy of Arts and Sciences (KNAW) has named American cancer researcher Bert Vogelstein as the very first recipient of the KNAW Bob Pinedo Cancer Care Award.
In the 1980s, Vogelstein demonstrated the genetic mechanism that leads to cancer. He is now working on cancer therapies that utilise the patient’s immune system. He is also developing genetic tests for early cancer detection.
About the laureate
Bert Vogelstein (born in Baltimore, USA, on 2 June 1949) is director of the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins Kimmel Cancer Center and Clayton Professor of Oncology and Pathology at Johns Hopkins University in Baltimore.
Vogelstein graduated summa cum laude in mathematics, but after an extra summer internship working on cancer research, he discovered that medicine was a better outlet for his passion.
Vogelstein has co-authored more than five hundred academic publications and more than one hundred patents. He is one of the most cited researchers in the world and has received dozens of distinctions, including the Breakthrough Prize in Life Sciences in 2013. Vogelstein is a member of the National Academy of Sciences and the European Molecular Biology Organization, among others.